Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity.

Datopotamab deruxtecan (Dato-DXd; 100 μg/mL) binds specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and Deruxtecan release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells in vitro.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Datopotamab deruxtecan (Dato-DXd; 6 mg/kg) shows potent antitumor activity with tumor regression in several TROP2-expressing xenograft tumors including NSCLC patient-derived xenograft (PDX) models. Safety profiles of Datopotamab deruxtecan in rats and cynomolgus monkeys are acceptable.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.  [Content Brief]